317 related articles for article (PubMed ID: 32340837)
1. Hydroxychloroquine in Covid-19: Does the end justify the means?
Yakoub-Agha I
Curr Res Transl Med; 2020 Aug; 68(3):81-82. PubMed ID: 32340837
[No Abstract] [Full Text] [Related]
2. Considerations for drug interactions on QTc interval in exploratory COVID-19 treatment.
Roden DM; Harrington RA; Poppas A; Russo AM
Heart Rhythm; 2020 Jul; 17(7):e231-e232. PubMed ID: 32302703
[No Abstract] [Full Text] [Related]
3. Safety considerations with chloroquine, hydroxychloroquine and azithromycin in the management of SARS-CoV-2 infection.
Juurlink DN
CMAJ; 2020 Apr; 192(17):E450-E453. PubMed ID: 32269021
[No Abstract] [Full Text] [Related]
4. How to manage rheumatic patients during the coronavirus pandemic.
Parisi S; Ditto MC; Finucci A; Fusaro E
Panminerva Med; 2020 Sep; 62(3):176-177. PubMed ID: 32343511
[No Abstract] [Full Text] [Related]
5. Use of Chloroquine and Hydroxychloroquine in COVID-19 and Cardiovascular Implications: Understanding Safety Discrepancies to Improve Interpretation and Design of Clinical Trials.
Oren O; Yang EH; Gluckman TJ; Michos ED; Blumenthal RS; Gersh BJ
Circ Arrhythm Electrophysiol; 2020 Jun; 13(6):e008688. PubMed ID: 32436730
[No Abstract] [Full Text] [Related]
6. Early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: A retrospective analysis of 1061 cases in Marseille, France.
Million M; Lagier JC; Gautret P; Colson P; Fournier PE; Amrane S; Hocquart M; Mailhe M; Esteves-Vieira V; Doudier B; Aubry C; Correard F; Giraud-Gatineau A; Roussel Y; Berenger C; Cassir N; Seng P; Zandotti C; Dhiver C; Ravaux I; Tomei C; Eldin C; Tissot-Dupont H; Honoré S; Stein A; Jacquier A; Deharo JC; Chabrière E; Levasseur A; Fenollar F; Rolain JM; Obadia Y; Brouqui P; Drancourt M; La Scola B; Parola P; Raoult D
Travel Med Infect Dis; 2020; 35():101738. PubMed ID: 32387409
[TBL] [Abstract][Full Text] [Related]
7. Safety considerations for chloroquine and hydroxychloroquine in the treatment of COVID-19.
Gevers S; Kwa MSG; Wijnans E; van Nieuwkoop C
Clin Microbiol Infect; 2020 Sep; 26(9):1276-1277. PubMed ID: 32422406
[No Abstract] [Full Text] [Related]
8. Will Hydroxychloroquine Still Be a Game-Changer for COVID-19 by Combining Azithromycin?
Li C; Cheng G
Front Immunol; 2020; 11():1969. PubMed ID: 32849658
[TBL] [Abstract][Full Text] [Related]
9. Inpatient Use of Ambulatory Telemetry Monitors for COVID-19 Patients Treated With Hydroxychloroquine and/or Azithromycin.
Chang D; Saleh M; Gabriels J; Ismail H; Goldner B; Willner J; Beldner S; Mitra R; John R; Epstein LM
J Am Coll Cardiol; 2020 Jun; 75(23):2992-2993. PubMed ID: 32330546
[No Abstract] [Full Text] [Related]
10. COVID-19 and (hydroxy)chloroquine-azithromycin combination: Should we take the risk for our patients?
Javelot H; El-Hage W; Meyer G; Becker G; Michel B; Hingray C
Br J Clin Pharmacol; 2020 Jun; 86(6):1176-1177. PubMed ID: 32350872
[No Abstract] [Full Text] [Related]
11. Is Coronavirus Disease 2019 (COVID-19) seen less in countries more exposed to Malaria?
Sargin G; Yavaşoğlu Sİ; Yavasoglu I
Med Hypotheses; 2020 Jul; 140():109756. PubMed ID: 32344306
[No Abstract] [Full Text] [Related]
12. Immune Modulation as a Therapeutic Option During the SARS-CoV-2 Outbreak: The Case for Antimalarial Aminoquinolines.
Vitte J; Michel M; Mezouar S; Diallo AB; Boumaza A; Mege JL; Desnues B
Front Immunol; 2020; 11():2159. PubMed ID: 32983179
[TBL] [Abstract][Full Text] [Related]
13. Virological and clinical cure in COVID-19 patients treated with hydroxychloroquine: A systematic review and meta-analysis.
Sarma P; Kaur H; Kumar H; Mahendru D; Avti P; Bhattacharyya A; Prajapat M; Shekhar N; Kumar S; Singh R; Singh A; Dhibar DP; Prakash A; Medhi B
J Med Virol; 2020 Jul; 92(7):776-785. PubMed ID: 32297988
[TBL] [Abstract][Full Text] [Related]
14. Covid-19 treatment update: follow the scientific evidence.
Becker RC
J Thromb Thrombolysis; 2020 Jul; 50(1):43-53. PubMed ID: 32338320
[No Abstract] [Full Text] [Related]
15. In vitro testing of combined hydroxychloroquine and azithromycin on SARS-CoV-2 shows synergistic effect.
Andreani J; Le Bideau M; Duflot I; Jardot P; Rolland C; Boxberger M; Wurtz N; Rolain JM; Colson P; La Scola B; Raoult D
Microb Pathog; 2020 Aug; 145():104228. PubMed ID: 32344177
[TBL] [Abstract][Full Text] [Related]
16. Chloroquine and hydroxychloroquine in covid-19.
Ferner RE; Aronson JK
BMJ; 2020 Apr; 369():m1432. PubMed ID: 32269046
[No Abstract] [Full Text] [Related]
17. Cardiovascular Safety of Potential Drugs for the Treatment of Coronavirus Disease 2019.
Aggarwal G; Henry BM; Aggarwal S; Bangalore S
Am J Cardiol; 2020 Aug; 128():147-150. PubMed ID: 32425199
[TBL] [Abstract][Full Text] [Related]
18. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Gautret P; Lagier JC; Parola P; Hoang VT; Meddeb L; Mailhe M; Doudier B; Courjon J; Giordanengo V; Vieira VE; Tissot Dupont H; Honoré S; Colson P; Chabrière E; La Scola B; Rolain JM; Brouqui P; Raoult D
Int J Antimicrob Agents; 2020 Jul; 56(1):105949. PubMed ID: 32205204
[TBL] [Abstract][Full Text] [Related]
19. Silencing of immune activation with methotrexate in patients with COVID-19.
Safavi F; Nath A
J Neurol Sci; 2020 Aug; 415():116942. PubMed ID: 32471659
[No Abstract] [Full Text] [Related]
20. Hydroxychloroquine and azithromycin as potential treatments for COVID-19; clinical status impacts the outcome.
Okour M; Al-Kofahi M; Austin D
J Pharmacokinet Pharmacodyn; 2020 Jun; 47(3):187-188. PubMed ID: 32405664
[No Abstract] [Full Text] [Related]
[Next] [New Search]
